Events

Improving healthcare with data collected from medicine and vaccine adverse event reporting.

Real world evidence in the regulation of medical devices.

A presentation on current activities, collaborations, and performance of the Prescription Medicine Authorisation Branch.

The increasing availability of Real World Evidence presents opportunities to improve treatments and repurpose medicines.

Post Market Surveillance - Considerations for medical device sponsors.

Updates on regulatory framework and key activities from the TGA's Medical Devices Authorisation Branch.

Updates on regulatory pathways for gene therapy products in Australia.

Updates on key activities for the TGA's Manufacturing Quality Branch.

Updates on current activities and focus areas for the Complementary and Over the Counter Medicines Branch.

Lessons learnt from COVID-19 to improve future vaccine development.

Current progress in establishing the Australian Unique Device Identification (UDI) System.

Patient-Matched Medical Devices (PMMDs) - key regulatory considerations.

A presentation discussing the lessons learnt from the Actemra (tocilizumab) shortage.

TGA speaker opportunity at ARCS conference.

Current considerations for regulating the design and development of software based medical devices.

Advisory Committee on Vaccines (ACV) meeting

Guest speakers presented on their experiences in implementing UDI in healthcare.

Presentation on medical device regulations.

A webinar to provide an overview on the new Good Clinical Practice (GCP) Inspection Program guidance document.

Information webinar including questions and answers, to discuss and share guest speaker experience from Arthrex.

Information on the new requirements for medicinal cannabis products in Australia.

Advisory Committee on Medicines (ACM) meeting

Guidance material about exporting therapeutic goods from Australia that aligns with current legislation, policy and business operations.

TGA presentation slides from eMedication Management Conference, Sydney (29-30 March 2022).

Webinar presentation : updated evidence guidelines for listed medicines